The U.S. colorectal cancer screening market is evolving rapidly, driven by advancements in diagnostic technologies and increasing awareness of early detection benefits. Industry growth is supported by robust innovations in non-invasive screening methods and expanding screening programs across clinical settings, aligning with rising demand for accurate and patient-friendly diagnostics.
Market Size and Overview
The global U.S. colorectal cancer screening market size is estimated to be valued at USD 6.41 billion in 2025 and is expected to reach USD 10.77 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.0% from 2025 to 2032.
The U.S. Colorectal Cancer Screening Market growth is propelled by the integration of molecular diagnostics with traditional screening and the increasing adoption of stool-based and blood-based diagnostic tests. The increasing prevalence of colorectal cancer and supportive government screening initiatives contribute significantly to market growth, highlighting promising market opportunities.
Market Segments and Analysis
The U.S. colorectal cancer screening market encompasses three core segments: Screening Technique, End User, and Product Type.
- Screening Technique: Includes colonoscopy, fecal immunochemical test (FIT), stool DNA testing, and CT colonography. Colonoscopy remains the dominant segment with widespread clinical acceptance, contributing significantly to market revenue in 2024. However, stool DNA testing is the fastest-growing technique due to its non-invasive nature and increased consumer preference, as demonstrated by Novigenix SA’s rising sales in 2025.
- End User: Hospital-based screenings, diagnostic laboratories, and ambulatory surgical centers form this segment. Hospitals hold the dominant position given their extensive infrastructure and patient influx, but diagnostic laboratories are witnessing rapid growth, powered by improved genetic testing capabilities and turnaround times.
- Product Type: Encompasses reagents & kits, consumables, and instruments & devices. Reagents & kits lead the market in revenue owing to continual innovation and demand for high-precision tests, with Quidel Corporation expanding its reagent portfolio in 2024 to meet this growth.
Market Drivers
One prominent market driver is the rising adoption of minimally invasive colorectal cancer screening techniques coupled with regulatory support and reimbursement initiatives. In 2024, the U.S. Preventive Services Task Force (USPSTF) updated screening recommendations to include molecular stool tests, boosting patient uptake and acceptance. According to health data, non-invasive screening adoption increased by nearly 15% from 2023 to 2025, reinforcing the important market dynamics fostering business growth in the colorectal cancer screening market.
Segment Analysis: Screening Technique
Focusing on the screening technique segment, colonoscopy, despite its invasive procedure nature, dominates market revenue due to its comprehensive diagnostic capability. Nevertheless, stool DNA testing is the fastest-growing sub-segment, presenting double-digit growth in market revenue in 2024. Novigenix SA’s recent product launch of an advanced multi-target stool DNA test significantly expanded market scope by increasing patient compliance and diagnostic accuracy, as observed in regional healthcare networks.
Consumer Behavior Insights
Recent consumer behavior analysis from 2024 to 2025 reveals compelling shifts in colorectal cancer screening preferences. Firstly, patients exhibit increased inclination towards non-invasive, home-based testing options, supported by surveys showing a 20% rise in mail-in stool test kits usage. Secondly, there is growing sensitivity towards screening costs, prompting laboratories to optimize pricing models for increased accessibility. Lastly, sustainability has emerged as a consideration, with consumers favoring providers incorporating eco-friendly materials in test kits—a trend observed in product redesigns by market companies like Quidel Corporation.
Key Players
The market players steering the U.S. colorectal cancer screening market include Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Quidel Corporation, and Novigenix SA among others. In 2024 and 2025, these companies have intensified market growth strategies by launching novel testing products, expanding manufacturing capacities, and entering untapped regional segments. For instance, Quidel Corporation launched an enhanced FIT reagent in 2024, resulting in increased market revenue and customer retention.
Key Winning Strategies Adopted by Key Players
Innovative market growth strategies differentiate the leading players. Polymedco Inc., in 2025, implemented AI-driven predictive analytics integrated with colonoscopy devices to enhance screening outcomes, leading to improved diagnostic accuracy and a 12% increase in customer adoption. Similarly, Eiken Chemical Co. Ltd. adopted a strategic partnership model with local healthcare providers in 2024 to expand home-based stool testing access, resulting in significant regional penetration. Another impactful strategy was Novigenix SA’s investment in precision biomarker identification technologies in 2025, enabling more personalized screening protocols and driving elevated patient compliance.
---
FAQs
Q1: Who are the dominant players in the U.S. colorectal cancer screening market?
Key market players include Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Quidel Corporation, and Novigenix SA. These players lead through continuous product innovation and expansion initiatives observed prominently in 2024–2025.
Q2: What will be the size of the U.S. colorectal cancer screening market in the coming years?
The U.S. colorectal cancer screening market size is anticipated to grow from USD 6.41 billion in 2025 to USD 10.77 billion by 2032, with a CAGR of 8.0%, driven by evolving diagnostic technologies and enhanced screening uptake.
Q3: Which end-user sector holds the largest growth opportunity in the U.S. colorectal cancer screening market?
Diagnostic laboratories represent the fastest-growing end-user segment due to advances in genetic and molecular testing, coupled with faster processing times and increased accessibility.
Q4: How will market development trends evolve in the next five years?
Market trends will increasingly favor non-invasive, molecular-based screening methods, AI integration for diagnostics, and home-based testing solutions, reflecting evolving consumer preferences and technological innovations.
Q5: What challenges exist in the competitive landscape of the U.S. colorectal cancer screening market?
Challenges include regulatory compliance complexities, pricing pressures, and maintaining accuracy while expanding non-invasive test adoption, requiring market companies to focus on innovation and strategic partnerships.
Q6: What go-to-market strategies are commonly adopted in the U.S. colorectal cancer screening market?
Market companies often deploy new product development, capacity expansion, and regional collaboration strategies. Notably, AI integration and targeted biomarker innovations are unique approaches enhancing market positioning.
Get more insights on : U.S. Colorectal Cancer Screening Market
Get this Report in Japanese Language: 米国大腸がん検査市場-
Get this Report in Korean Language: 미국대장암검진시장
Read More Related Articles : Intensive Care Beds: The Unsung Heroes in Healthcare System
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )
Comments
0 comment